Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800259 | 0.88 | SLC7A5 (0.46) | MAPTACETSHRLDHASLC7A5 | |
| SCHEMBL2672622 | 0.86 | PPARG (0.47) | MAPTLDHAPPARGPPARA | |
| SCHEMBL2672561 | 0.86 | CYP19A1 (0.46) | MAPTMMP8LDHA | |
| SCHEMBL2828887 | 0.86 | LDHA (0.44) | MAPTMMP8NPC1RAB9ALDHA | |
| SCHEMBL11274903 | 0.86 | LDHA (0.44) | MAPTACETRPA1TSHRLDHA | |
| SCHEMBL2672698 | 0.85 | LDHA (0.67) | MAPTLDHAPPARGPPARA | |
| SCHEMBL2672684 | 0.84 | HCAR2 (0.42) | MAPTMMP8PPARGPPARA | |
| SCHEMBL2672604 | 0.84 | PNMT (0.48) | MAPTMDM2PPARGPPARA | |
| SCHEMBL2673427 | 0.84 | MAPT (0.49) | MAPTMMP8TSHRNPC1RAB9A | |
| SCHEMBL2672361 | 0.83 | TAAR1 (0.51) | MAPTCYP1A2LDHAPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850787-A | Recyclable aramid nanofiber aerogel, and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2023-03-28 | — | — | CN | claimed |
| CN-110234656-B | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-110214139-B | Process for producing triazolopyridine compound | 日本烟草产业株式会社 | 2022-08-23 | — | — | CN | disclosed |
| CN-106518673-A | Synthesis method of propafenone drug intermediate benzylmalonic acid diethyl ester | 厦门市凯尔利信息科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-106518673-A | Synthesis method of propafenone drug intermediate benzylmalonic acid diethyl ester | 厦门市凯尔利信息科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-8257931-B2 | Regulation of protein synthesis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-09-04 | — | — | US | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20100144805-A1 | Regulation of protein synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-10 | — | — | US | disclosed |
| US-5312838-A | β-alanineamide aryl/alkylsulfide/sulfonyl-terminated amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1994-05-17 | — | — | US | disclosed |
| US-5268391-A | Cardiovascular disorders | C. D. SEARLE & CO. (US) | 1993-12-07 | — | — | US | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5246969-A | Oligopeptides as renin inhibitors | G. D. SEARLE & CO. (US) | 1993-09-21 | — | — | US | disclosed |
| US-4931591-A | Novel 5-amino-4-hydroxyvaleryl derivatives | CIBA-GEIGY CORPORATION (US) | 1990-06-05 | — | — | US | disclosed |
| US-4914129-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
| US-4889869-A | ANTIALDOSTERONISM AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| US-4758584-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| US-4536548-A | ACRYLIC ESTER POLYMERS | CHEMISCHE WERKE HUELS, A.G. (DE) | 1985-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ACMSD, ACACA, ALDH1A1 | MAPT 2195/4885MMP8 4312/4885MDM2 1787/4885 |
| US-20100144805-A1 | Regulation of protein synthesis | EIF4EBP1, RNMT, NCBP1 | MAPT 3352/4885MMP8 3476/4885MDM2 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.